Pharmaceuticals News and Research

RSS

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

Myelodysplastic syndromes - a group of serious blood cancers - are nearly five times more common in seniors than previously thought, according to a new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center.

27 Apr 2010

New health law will require industry to disclose payments to physicians

Doctors who accept speaking fees, five-star meals and other compensation from pharmaceutical or medical device companies will soon see their names - and the value of the gifts they accept - revealed on the Web, under a new federal law that follows several states in drawing attention to such financial benefits" (Weintraub, 4/26).

27 Apr 2010

Costs, effects on business questioned as health overhaul analysis continues

The Associated Press: The biggest unanswered question in the health overhaul debate remains what the new law will mean for ordinary Americans. "Many experts believe the law falls short on taming costs, and that will force Congress to revisit health care in a few years.

27 Apr 2010

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Catalyst Pharmaceutical Partners, Inc. announced today that it has received notice from The NASDAQ Stock Market confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

A first step in the long road to health reform

Australia provides good health care to the majority of its citizens most of the time and compares well with like countries. The capacity for illness to destroy families financially, seen in the US and in many less economically advanced countries where governments make small or no contributions to the cost of health care, is much diminished by Medicare, public hospitals and subsidised pharmaceuticals.

27 Apr 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Urigen Pharmaceuticals secures debt held by Platinum-Montaur Life Sciences

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the secured debt held by Platinum-Montaur Life Sciences, LLC has been converted into a newly created Series C Preferred Stock of the Company. As a result of the conversion, the lien on the Company's assets, including its intellectual property will be extinguished.

26 Apr 2010

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Pro-Tect Pharmaceuticals, Inc. announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

26 Apr 2010

The Frost Group agrees to make investment in ChromaDex

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, announced today The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex.

26 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.

26 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Intellect Neurosciences completes restructuring of balance sheet

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today it has completed a restructuring of its balance sheet. The result is the extinguishment of approximately $24 million of aggregate face amount plus accrued interest of debt and preferred stock through the issuance of common stock.

26 Apr 2010

Pharmaceuticals News and Research

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

New health law will require industry to disclose payments to physicians

Costs, effects on business questioned as health overhaul analysis continues

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

A first step in the long road to health reform

Stinging FDA review for Acurox – the implications

Urigen Pharmaceuticals secures debt held by Platinum-Montaur Life Sciences

PRTT completes acquisition of multiple patents and patents-pending from Nectid

The Frost Group agrees to make investment in ChromaDex

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Intellect Neurosciences completes restructuring of balance sheet

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence